WO2016123733A1 - 绿原酸在制备治疗卵黄囊瘤的药物中的用途 - Google Patents

绿原酸在制备治疗卵黄囊瘤的药物中的用途 Download PDF

Info

Publication number
WO2016123733A1
WO2016123733A1 PCT/CN2015/072100 CN2015072100W WO2016123733A1 WO 2016123733 A1 WO2016123733 A1 WO 2016123733A1 CN 2015072100 W CN2015072100 W CN 2015072100W WO 2016123733 A1 WO2016123733 A1 WO 2016123733A1
Authority
WO
WIPO (PCT)
Prior art keywords
chlorogenic acid
tumor
yolk sac
treating
sac tumor
Prior art date
Application number
PCT/CN2015/072100
Other languages
English (en)
French (fr)
Inventor
张洁
贾静
黄望
Original Assignee
四川九章生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 四川九章生物科技有限公司 filed Critical 四川九章生物科技有限公司
Priority to PCT/CN2015/072100 priority Critical patent/WO2016123733A1/zh
Publication of WO2016123733A1 publication Critical patent/WO2016123733A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate

Definitions

  • the invention relates to the use of chlorogenic acid for the preparation of a medicament for treating yolk sac tumor.
  • Yolk sac tumor also known as endodermal sinus tumor, accounts for about 20% of primordial germ cell tumors. It belongs to a highly malignant tumor that can occur in all ages and is more common in children and young women. The patient's clinical manifestations are abdominal mass, pain and ascites, and his ovarian function is rarely found abnormal. The disease is highly malignant and the disease develops rapidly. It has seriously threatened the life and health of patients. The disease is unilateral, the patient is right. The side attachment parts are common areas. The pathogenesis of the disease is not completely clear at present, some scholars believe that reproductive and pluripotent embryonic cells are the cause of the disease.
  • the technical solution of the present invention is to provide a new use of chlorogenic acid.
  • the medicament is prepared by using an effective amount of chlorogenic acid as an active ingredient, and adding a pharmaceutically acceptable auxiliary or auxiliary component.
  • the pharmaceutical preparation contains 1 to 3000 mg of chlorogenic acid per preparation unit.
  • the medicinal preparation uses chlorogenic acid in a dose of 1 to 100 mg/kg.
  • the agent is an oral preparation or an injection.
  • the chlorogenic acid of the invention can effectively treat yolk sac tumor, and the therapeutic effect at a higher dosage is equivalent to that of the chemotherapeutic drug cyclophosphamide, and it has been proved to be a safe drug with very small toxic and side effects, which can replace the traditional Chemotherapy for the treatment of yolk sac tumor can effectively solve the problem of traditional chemotherapeutic drugs for the treatment of yolk sac tumors with large side effects, and has good clinical application prospects.
  • FIG. 1 Expression of tumor markers AFP, PLAP, CK in the cytosol.
  • A expression of tumor marker AFP;
  • B expression of tumor marker PLAP;
  • C expression of tumor marker CK.
  • Test Example 1 Inhibition rate of chlorogenic acid on yolk sac tumor animal model
  • mice C57BL/6 mice, male, 18-22g, SPF grade, were raised in the common animal room of Experimental Animal Center of Sichuan University.
  • the feeding conditions should be in accordance with: GB 14925-2001, the animals were adapted for one week before the experiment; Animals are provided by the Experimental Animal Center of Sichuan University.
  • Mouse yolk sac tumor model C57BL/6 mice, male, 18-22 g.
  • the tumor tissues with good growth were taken, cut, ground, filtered, and diluted with a 1:3 ratio of sterile physiological saline to prepare a tumor cell suspension, and 0.2 ml of tumor solution was inoculated into the back of each mouse.
  • Animals were randomized the next day after inoculation, weighed, and dosing.
  • the cyclophosphamide injection was administered in an amount of 0.2 ml per 10 g of mouse peritoneal injection. Cyclophosphamide was injected once a day for the inoculation of cyclophosphamide.
  • the chlorogenic acid administration volume was intraperitoneal injection of 0.2 ml per 10 g of mice once a day for 28 days.
  • the experimental animals were divided into 5 groups, negative control group, cyclophosphamide 60 mg/kg administration group, chlorogenic acid 5 mg/kg, 10 mg/kg, and 20 mg/kg three dose groups. 10 animals per group. After the chlorogenic acid was stopped, the animals were sacrificed the next day, weighing, weighing and weighing. The tumor inhibition rate (%) was calculated from the tumor weight. Body weight and tumor weight mean ⁇ standard deviation Indicated and carried out between each administration group and the negative control group.
  • the medium and high dose group of chlorogenic acid has obvious inhibitory effect on the growth of mouse yolk sac tumor, and has a dose-effect relationship.
  • the inhibition rate of chlorogenic acid 20 mg/kg is similar to that of cyclophosphamide.
  • the chlorogenic acid of the present invention had no significant effect on animal body weight at all doses.
  • the experimental results show that the invention can effectively inhibit the yolk sac tumor, and the therapeutic effect of the high dose is equivalent to that of the chemotherapeutic drug cyclophosphamide, and the curative effect is good, and the effect on the animal body weight is not obvious, and the side effect is small.
  • Test Example 2 The efficacy test of chlorogenic acid of the present invention for treating yolk sac tumor
  • mice C57BL/6 mice, male, 18-22g, SPF grade, were raised in the common animal room of Experimental Animal Center of Sichuan University.
  • the feeding conditions should be in accordance with: GB 14925-2001, the animals were adapted for one week before the experiment; Animals are provided by the Experimental Animal Center of Sichuan University.
  • Mouse yolk sac tumor model C57BL/6 mice, male, 18-22 g.
  • the tumor tissues with good growth were taken, cut, ground, filtered, and diluted with a 1:3 ratio of sterile physiological saline to prepare a tumor cell suspension, and 0.2 ml of tumor solution was inoculated into the back of each mouse.
  • Animals were randomized the next day after inoculation, weighed, and dosing.
  • the cyclophosphamide injection was administered in an amount of 0.2 ml per 10 g of mouse peritoneal injection. Cyclophosphamide was injected once a day for the inoculation of cyclophosphamide.
  • the chlorogenic acid administration volume was intraperitoneal injection of 0.2 ml per 10 g of mice once a day for 28 days.
  • mice The experimental animals were divided into 5 groups: normal control group (NC group), cyclophosphamide 60 mg/kg administration group, chlorogenic acid 5 mg/kg, 10 mg/kg, and 20 mg/kg three dose groups. 10 animals per group. See Table 2
  • the immunohistochemical procedure was carried out according to the instructions provided by the SP kit, and the primary antibody concentrations of AFP, PLAP, and CK were 1:100. Image analysis was performed using Image-pro plus software. Ten high power fields were randomly selected, the number of immunohistochemical positive cells was counted, and the optical density of positive cells was determined. Multiplying the two data is the expression value (OD) of the immunohistochemical staining of the sample being tested.
  • Tumor tissue markers showed Figure 1: Cytoplasmic staining was brownish yellow and positive. The average optical density values of the respective tumor markers were measured by an image analysis system using a section without the primary antibody as a negative control, as shown in Table 3.
  • Chlorogenic acid has a significant decrease in the expression of tumor markers of yolk sac tumors, which is similar to the chemotherapeutic drug cyclophosphamide, indicating that chlorogenic acid can effectively treat yolk sac tumors.
  • the chlorogenic acid of the invention can effectively treat yolk sac tumor, and the therapeutic effect at a higher dose is equivalent to that of the chemotherapeutic drug cyclophosphamide, and can be used instead of the traditional chemotherapeutic drug, with small side effects and good clinical application prospect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了绿原酸在制备治疗卵黄囊瘤的药物中的用途。绿原酸可有效治疗卵黄囊瘤，在较高给药剂量下的治疗效果与化疗药环磷酰胺相当，副作用较小，可替代传统化疗药物使用。

Description

绿原酸在制备治疗卵黄囊瘤的药物中的用途 技术领域
本发明涉及绿原酸在制备治疗卵黄囊瘤的药物中的用途。
背景技术
卵黄囊瘤又称内胚窦瘤，约占原始生殖细胞肿瘤20％，其属于一种高度恶性肿瘤，可发生于各年龄段，多见于儿童及年轻女性。患者临床以腹部包块、胀痛与腹水为主要表现，而其卵巢功能很少发现异常，该病因其恶性程度高且病情发展快，已严重威胁患者生命健康，该病单侧居多，患者右侧附件部位为常见区域。该病的发病机制当前尚不完全明确，部分学者认为生殖与多潜能胚胎细胞是致病源。
目前的治疗方法包括手术治疗和化疗，手术治疗通常针对瘤体积较大的卵黄囊瘤，瘤体积非常小的卵黄囊瘤可以采用化疗，而对经手术切除的原发性肿瘤患者，需要采用联合化疗的方式进一步治疗，常用的化疗药物有环磷酰胺、长春新碱、放线菌素等等。
然而，目前的化疗药物不仅会杀伤肿瘤细胞，还会对正常细胞有杀伤作用，副作用大，需要寻找新的药物。
未见绿原酸治疗卵黄囊瘤的报道。
发明内容
本发明的技术方案是提供了绿原酸的新用途。
本发明绿原酸在制备治疗卵黄囊瘤的药物中的用途。
其中，所述的药物是以有效量的绿原酸为活性成分，加上药学上可接受的辅料或者辅助性成分制备而成的制剂。
其中，所述的药物制剂中每制剂单位含有绿原酸1～3000mg。
其中，所述的药物制剂中绿原酸的使用剂量为1～100mg/kg。
其中，所述的药剂是口服制剂或者注射剂。
本发明绿原酸可以有效治疗卵黄囊瘤，在较高给药剂量下的治疗效果与化疗药环磷酰胺相当，而且其已经被证明是一种安全的药物，毒副作用非常小，可以替代传统化疗药物用于卵黄囊瘤的治疗，可以有效解决传统化疗药物治疗卵黄囊瘤存在副作用大的问题，临床应用前景良好。
显然，根据本发明的上述内容，按照本领域的普通技术知识和惯用手段，在不脱离本发明上述基本技术思想前提下，还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式，对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
附图说明
图1肿瘤标记物AFP、PLAP、CK在胞浆中的表达。A:肿瘤标记物AFP的表达；B:肿瘤标记物PLAP的表达；C:肿瘤标记物CK的表达。
具体实施方式
试验例1绿原酸对卵黄囊瘤动物模型的抑瘤率
一、实验材料
1.实验细胞及动物
实验细胞：人卵黄囊瘤细胞，由四川大学华西医院卫生部移植工程和移植免疫重点实验室提供。
实验动物：C57BL/6小鼠，雄性，18-22g，SPF级，饲养于四川大学实验动物中心普通动物房，饲养条件应符合：GB 14925-2001，动物在实验前适应性饲养一周；饲料及动物都由四川大学实验动物中心提供。
2.试剂与试药
培养基RPML1640(Gibco公司)，生理盐水(四川科伦药业股份有限公司)，环磷酰胺注射液(江苏恒瑞医药股份有限公司)，绿原酸(四川九章生物科技有限公司)。
二、实验方法
小鼠卵黄囊瘤模型，选用C57BL/6小鼠，雄性，18-22g。实验时，取生长良好的肿瘤组织，剪碎，研磨，过滤，用无菌生理盐水按1：3比例稀释后制成肿瘤细胞悬液，每只小鼠腋背部接种0.2ml瘤液。接种后次日动物随机分组，称重，并开始给药。环磷酰胺注射液给药体积为每10g小鼠腹腔注射0.2ml。环磷酰胺于接种次日注射环磷酰胺1次。绿原酸给药体积为每10g小鼠腹腔注射0.2ml，每日1次，连续给药28天。
实验动物共分5组，阴性对照组、环磷酰胺60mg/kg给药组、绿原酸5mg/kg，10mg/kg，20mg/kg三个剂量组。每组10只动物。绿原酸停药后次日处死动物，称体重，剥瘤并称瘤重。根据肿瘤重量计算肿瘤抑制率(％)。体重及瘤重用均值±标准差
Figure PCTCN2015072100-appb-000001
表示，并进行各给药组与阴性对照组之间。
三、实验结果
结果如表1所示：
表1.绿原酸对小鼠卵黄囊瘤的抗肿瘤作用
Figure PCTCN2015072100-appb-000002
注：***P<0.001，与阴性对照组比较。###P<0.001，与环磷酰胺组比较。
本发明绿原酸中、高剂量组对小鼠卵黄囊瘤的生长有明显的抑制作用，且呈一定的剂量效应关系，绿原酸20mg/kg抑瘤率与环磷酰胺抑瘤率相近。同时，本发明绿原酸在所有剂量下对动物体重无明显影响。
实验结果说明，本发明可以有效抑制卵黄囊瘤，高剂量的治疗效果与化疗药环磷酰胺相当，疗效好，且对动物体重无明显影响，副作用小。
试验例2本发明绿原酸治疗卵黄囊瘤的药效实验
一、实验材料
1.实验细胞及动物
实验细胞：人卵黄囊瘤细胞，由四川大学华西医院卫生部移植工程和移植免疫重点实验室提供。
实验动物：C57BL/6小鼠，雄性，18-22g，SPF级，饲养于四川大学实验动物中心普通动物房，饲养条件应符合：GB 14925-2001，动物在实验前适应性饲养一周；饲料及动物都由四川大学实验动物中心提供。
2.试剂与试药
培养基RPML1640(Gibco公司)，SP试剂盒，生理盐水(四川科伦药业股份有限公司)，环磷酰胺注射液(江苏恒瑞医药股份有限公司)，绿原酸(四川九章生物科技有限公司)。
二、实验方法
小鼠卵黄囊瘤模型，选用C57BL/6小鼠，雄性，18-22g。实验时，取生长良好的肿瘤组织，剪碎，研磨，过滤，用无菌生理盐水按1：3比例稀释后制成肿瘤细胞悬液，每只小鼠腋背部接种0.2ml瘤液。接种后次日动物随机分组，称重，并开始给药。环磷酰胺注射液给药体积为每10g小鼠腹腔注射0.2ml。环磷酰胺于接种次日注射环磷酰胺1次。绿原酸给药体积为每10g小鼠腹腔注射0.2ml，每日1次，连续给药28天。
实验动物共分5组，正常对照组(NC组)、环磷酰胺60mg/kg给药组、绿原酸5mg/kg，10mg/kg，20mg/kg三个剂量组。每组10只动物。见表2
表2.实验分组、给药方式及给药量(注：所有给药组的给药体积相同)
Figure PCTCN2015072100-appb-000003
免疫组织化学步骤参照SP试剂盒提供的说明书进行，AFP、PLAP、CK的一抗浓度均为1：100。用Image-pro plus软件进行图像分析。随机选取10个高倍视野，计数免疫组织化学阳性细胞数及测定阳性细胞的光密度。将两项数据相乘即为所测样本的免疫组织化学染色的相对定量结果(expression value，OD)。
统计学处理，采用SPSS12.0统计软件进行相关分析，组间差异比较用方差分析检验。
三、实验结果
肿瘤组织标记物显示图1：胞质染色棕黄色，呈阳性反应。以不加一抗的切片为阴性对照，通过图像分析系统测出各个肿瘤标记物的平均光密度值，分别如表3所示。
表3.各组肿瘤标记物的平均吸光度
Figure PCTCN2015072100-appb-000004
注：**P<0.01，与NC组比较。
以上结果显示，与正常对照组比较，环磷酰胺组、绿原酸高、中、低各剂量组均明显降低AFP、PLAP、CK的表达。其中，绿原酸高剂量组(20mg/kg)与环磷酰胺组较为接近。
四、结论
绿原酸对于卵黄囊瘤的肿瘤标记物具有明显的降低表达作用，与化疗药环磷酰胺较为接近，说明绿原酸可以有效治疗卵黄囊瘤。
综上，本发明绿原酸可以有效治疗卵黄囊瘤，在较高剂量下的治疗效果与化疗药环磷酰胺相当，可以替代传统化疗药物使用，副作用小，临床应用前景良好。

Claims (5)

  1. 绿原酸在制备治疗卵黄囊瘤的药物中的用途。
  2. 根据权利要求1所述的用途，其特征在于：所述的药物是以有效量的绿原酸为活性成分，加上药学上可接受的辅料或者辅助性成分制备而成的制剂。
  3. 根据权利要求2所述的用途，其特征在于：所述的药物制剂中每制剂单位含有绿原酸1～3000mg。
  4. 根据权利要求3所述的用途，其特征在于：所述的药物制剂中绿原酸的使用剂量为1～100mg/kg。
  5. 根据权利要求3或4所述的用途，其特征在于：所述的药剂是口服制剂或者注射剂。
PCT/CN2015/072100 2015-02-02 2015-02-02 绿原酸在制备治疗卵黄囊瘤的药物中的用途 WO2016123733A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/072100 WO2016123733A1 (zh) 2015-02-02 2015-02-02 绿原酸在制备治疗卵黄囊瘤的药物中的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/072100 WO2016123733A1 (zh) 2015-02-02 2015-02-02 绿原酸在制备治疗卵黄囊瘤的药物中的用途

Publications (1)

Publication Number Publication Date
WO2016123733A1 true WO2016123733A1 (zh) 2016-08-11

Family

ID=56563284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/072100 WO2016123733A1 (zh) 2015-02-02 2015-02-02 绿原酸在制备治疗卵黄囊瘤的药物中的用途

Country Status (1)

Country Link
WO (1) WO2016123733A1 (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101147733A (zh) * 2006-09-21 2008-03-26 四川九章生物化工科技发展有限公司 绿原酸在制备具有治疗女性器官肿瘤功效的药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101147733A (zh) * 2006-09-21 2008-03-26 四川九章生物化工科技发展有限公司 绿原酸在制备具有治疗女性器官肿瘤功效的药物中的应用

Similar Documents

Publication Publication Date Title
US11090330B2 (en) Pharmaceutical solution having a toxicity-reducing effect for antitumor drugs, and pharmaceutical composition comprising same
CN105338973A (zh) 使用辅酶q10联合疗法治疗癌症
BR112021014112A2 (pt) Usos de composto pró-fármaco de don e inibidor de ponto de controle imunológico para tratar câncer, bem como composto e composição farmacêutica compreendendo o mesmo
CN104398526B (zh) 雷公藤甲素和雷公藤红素在制备抗肿瘤药物中的应用
TW202038932A (zh) 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物
WO2015172712A1 (zh) 维生素c与抗肿瘤药物协同作用的注射用药物组合物
AU2016390488B9 (en) Application of dimethylamino micheliolide
WO2021169974A1 (zh) 一种抗双重打击淋巴瘤的联合用药物组合物及其应用
CN105380956B (zh) 一种治疗白血病的含艾德拉尼的药物组合物及应用
CN110664807B (zh) 一种具有协同抗黑色素瘤功效的药物组合物及其应用
CN109419803A (zh) 细胞自噬抑制剂与阿法替尼药物组合物及其在制备肿瘤增效制剂中的用途
EP1944039A1 (en) Drug for treating tumor and use thereof in the manufature of medicaments for treating tumor
CN109793727A (zh) 一种有效抗恶性肿瘤的药物组合物及其应用
CN109730983A (zh) 丹叶大黄素在制备治疗脓毒症药物中的应用
WO2016123733A1 (zh) 绿原酸在制备治疗卵黄囊瘤的药物中的用途
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
ES2275647T3 (es) Diantraquinonas policiclicas como agentes anti-cancerosos y anti-angiogenicos.
CN111110675A (zh) 延胡索乙素在制备抗奥沙利铂外周神经毒性药物中的应用
CN102614180A (zh) 伊曲康唑在制备治疗多发性骨髓瘤药物中的应用
CN108992463A (zh) 一种治疗肺癌的组合物及药物制剂
WO2019037671A1 (zh) 一种治疗癌症的联合用药物
CN115337308B (zh) Acss2抑制剂在制备抗h1n1亚型猪流感病毒药物中的应用
CN107320471A (zh) 一种治疗结核病的环丝氨酸药物组合物及其应用
CN101797242A (zh) 半胱胺在制备治疗癌症的药物中的应用
CN109646435B (zh) 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15880689

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15880689

Country of ref document: EP

Kind code of ref document: A1